PCAC meetingupcoming

PCAC “D-Day” for BPC-157 + TB-500 — Bulk Substances ruling

Thursday, July 23, 2026 · FDA

FDA Pharmacy Compounding Advisory Committee (PCAC) reviews BPC-157, TB-500, Thymosin α-1 and other peptides for inclusion on the 503A/503B compounding bulk substances list. The 'D-Day' for compounded recovery peptides.

Peptides affected

  • BPC-157
  • TB-500
  • Thymosin α-1
  • CJC-1295
  • Ipamorelin
  • KPV

Sources & further reading

Regulatory event entry on peptide regulatory calendar. Event details may change as the agency publishes updates — verify against the primary source above before acting on the timeline.